• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by DBV Technologies S.A. (Amendment)

    2/14/22 4:36:32 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DBVT alert in real time by email
    SC 13G/A 1 d239538dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 5)*

     

     

    DBV Technologies S.A.

    (Name of Issuer)

    Ordinary shares, €0.10 nominal value per share

    (Title of Class of Securities)

    23306J101 (American Depositary Shares, each representing one-half of one Ordinary Share)

    (CUSIP Number)

    December 31, 2021

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [ ] Rule 13d-1(b)

    [X] Rule 13d-1(c)

    [ ] Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    Page 2 of 9

     

    CUSIP No. 23306J101

     

      1    

      Name of reporting persons.

     

      Boxer Capital, LLC

      2  

      Check the appropriate box if a member of a group. (See instructions)

     

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only.

     

      4  

      Citizenship or place of organization.

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      Sole voting power.

     

      -0-

       6  

      Shared voting power.

     

      1,067,299*

       7  

      Sole dispositive power.

     

      -0-

       8  

      Shared dispositive power.

     

      1,067,299*

      9    

      Aggregate amount beneficially owned by each reporting person.

     

      1,067,299*

    10  

      Check box if the aggregate amount in row (9) excludes certain shares (see instructions).

     

      ☐

    11  

      Percent of class represented by amount in row (9).

     

      1.9%**

    12  

      Type of reporting person

     

      OO

     

    *

    Comprised of ordinary shares held through American Depository Shares, each of which represents one-half of an ordinary share.

    **

    Based on 55,011,687 ordinary shares outstanding as of October 26, 2021, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on October 26, 2021.


    Page 3 of 9

     

    CUSIP No. 23306J101

     

      1    

      Name of reporting persons.

     

      Boxer Asset Management Inc.

      2  

      Check the appropriate box if a member of a group. (See instructions)

     

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only.

     

      4  

      Citizenship or place of organization.

     

      Bahamas

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      Sole voting power.

     

      -0-

       6  

      Shared voting power.

     

      1,067,299*

       7  

      Sole dispositive power.

     

      -0-

       8  

      Shared dispositive power.

     

      1,067,299*

      9    

      Aggregate amount beneficially owned by each reporting person.

     

      1,067,299*

    10  

      Check box if the aggregate amount in row (9) excludes certain shares (see instructions).

     

      ☐

    11  

      Percent of class represented by amount in row (9).

     

      1.9%**

    12  

      Type of reporting person

     

      CO

     

    *

    Comprised of ordinary shares held through American Depository Shares, each of which represents one-half of an ordinary share.

    **

    Based on 55,011,687 ordinary shares outstanding as of October 26, 2021, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the SEC on October 26, 2021.


    Page 4 of 9

     

    CUSIP No. 23306J101

     

      1    

      Name of reporting persons.

     

      Joe Lewis

      2  

      Check the appropriate box if a member of a group. (See instructions)

     

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only.

     

      4  

      Citizenship or place of organization.

     

      United Kingdom

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      Sole voting power.

     

      -0-

       6  

      Shared voting power.

     

      1,067,299*

       7  

      Sole dispositive power.

     

      -0-

       8  

      Shared dispositive power.

     

      1,067,299*

      9    

      Aggregate amount beneficially owned by each reporting person.

     

      1,067,299*

    10  

      Check box if the aggregate amount in row (9) excludes certain shares (see instructions).

     

      ☐

    11  

      Percent of class represented by amount in row (9).

     

      1.9%**

    12  

      Type of reporting person

     

      IN

     

    *

    Comprised of ordinary shares held through American Depository Shares, each of which represents one-half of an ordinary share.

    **

    Based on 55,011,687 ordinary shares outstanding as of October 26, 2021, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the SEC on October 26, 2021.


    Page 5 of 9

     

    CUSIP No. 23306J101

     

      1    

      Name of reporting persons.

     

      MVA Investors, LLC

      2  

      Check the appropriate box if a member of a group. (See instructions)

     

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only.

     

      4  

      Citizenship or place of organization.

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      Sole voting power.

     

      -0-

       6  

      Shared voting power.

     

      -0-

       7  

      Sole dispositive power.

     

      -0-

       8  

      Shared dispositive power.

     

      -0-

      9    

      Aggregate amount beneficially owned by each reporting person.

     

      -0-

    10  

      Check box if the aggregate amount in row (9) excludes certain shares (see instructions).

     

      ☐

    11  

      Percent of class represented by amount in row (9).

     

      0.0%

    12  

      Type of reporting person

     

      OO

     


    Page 6 of 9

     

    CUSIP No. 23306J101

     

      1    

      Name of reporting persons.

     

      Aaron I. Davis

      2  

      Check the appropriate box if a member of a group. (See instructions)

     

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only.

     

      4  

      Citizenship or place of organization.

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      Sole voting power.

     

      -0-

       6  

      Shared voting power.

     

      -0-

       7  

      Sole dispositive power.

     

      -0-

       8  

      Shared dispositive power.

     

      -0-

      9    

      Aggregate amount beneficially owned by each reporting person.

     

      -0-

    10  

      Check box if the aggregate amount in row (9) excludes certain shares (see instructions).

     

      ☐

    11  

      Percent of class represented by amount in row (9).

     

      0.0%

    12  

      Type of reporting person

     

      IN

     


    Page 7 of 9

     

    This Amendment No. 5 (“Amendment No. 5”) amends and supplements the statement on Schedule 13G initially filed on December 20, 2018 (the “Original Filing”) by Boxer Capital, LLC (“Boxer Capital”), Boxer Asset Management Inc. (“Boxer Management”) and Joe Lewis, as amended by Amendment No. 1 filed on February 14, 2019 by Boxer Capital, Boxer Management and Joe Lewis, Amendment No. 2 filed on October 11, 2019 by Boxer Capital, Boxer Management, Joe Lewis and MVA Investors, LLC (“MVA Investors”), Amendment No. 3 filed on February 14, 2020 by Boxer Capital, Boxer Management, Joe Lewis, MVA Investors and Aaron Davis (collectively, the “Reporting Persons”) and Amendment No. 4 filed on February 16, 2021 by the Reporting Persons. The Original Filing, as amended, remains in effect except to the extent that it is amended, restated or superseded by information contained in this Amendment No. 5. Capitalized terms used and not defined in this Amendment No. 5 have the meanings set forth in the Original Filing, as amended.

    Item 4. Ownership.

    (a) Amount beneficially owned:

    Boxer Capital, Boxer Management and Joe Lewis beneficially own 1,067,299 Ordinary Shares, held through 2,134,598 ADS. MVA Investors and Aaron Davis do not beneficially own any Ordinary Shares.

    (b) Percent of class:

    The number of Ordinary Shares beneficially owned by Boxer Capital, Boxer Management and Joe Lewis represents 1.9% of the Issuer’s outstanding Ordinary Shares based on 55,011,687 Ordinary Shares outstanding as of October 26, 2021, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with SEC on October 26, 2021.

    (c) Number of Ordinary Shares as to which such person has:

     

      (i)

    Sole power to vote or to direct the vote:

    None of the Reporting Persons has sole power to vote or to direct the vote of Ordinary Shares.

     

      (ii)

    Shared power to vote or to direct the vote:

    Boxer Capital, Boxer Management and Joe Lewis have shared power to vote or to direct the vote of the 1,067,299 Ordinary Shares they beneficially own.

     

      (iii)

    Sole power to dispose or to direct the disposition of:

    None of the Reporting Persons has sole power to dispose or to direct the disposition of any Ordinary Shares.

     

      (iv)

    Shared power to dispose or to direct the disposition of:

    Boxer Capital, Boxer Management and Joe Lewis have shared power to dispose or to direct the disposition of the 1,067,299 Ordinary Shares they beneficially own.

    Item 5. Ownership of Five Percent or Less of a Class.

    With respect to each Reporting Person:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following  ☒.


    Page 8 of 9

     

    Item 10. Certification.

    (c) By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Exhibits

     

      1

    Joint Filing Agreement, dated February 14, 2020, among the Reporting Persons, incorporated by reference to Exhibit 1 to the Schedule 13G filed by the Reporting Persons on February 14, 2020.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    February 14, 2022

     

    BOXER CAPITAL, LLC
    By:  

    /s/ Aaron I. Davis

    Name:   Aaron I. Davis
    Title:   Chief Executive Officer
    BOXER ASSET MANAGEMENT INC.
    By:  

    /s/ Jason Callender

    Name:   Jason Callender
    Title:   Director
    JOSEPH C. LEWIS

    /s/ Joseph C. Lewis

    Joseph C. Lewis, Individually
    MVA INVESTORS, LLC
    By:  

    /s/ Aaron I. Davis

    Name:   Aaron I. Davis
    Title:   Authorized Signatory
    AARON I. DAVIS

    /s/ Aaron I. Davis

    Aaron I. Davis, Individually
    Get the next $DBVT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $DBVT

    DatePrice TargetRatingAnalyst
    5/29/2025$7.25Sell
    Goldman
    1/4/2023Hold → Buy
    Societe Generale
    12/16/2022Neutral → Sell
    Goldman
    5/10/2022$6.00 → $1.50Buy → Neutral
    Goldman
    12/21/2021$8.00 → $5.00Market Outperform
    JMP Securities
    12/21/2021$14.00 → $10.00Buy
    HC Wainwright & Co.
    9/14/2021Hold → Buy
    Societe Generale
    More analyst ratings

    $DBVT
    SEC Filings

    See more
    • SEC Form 8-K filed by DBV Technologies S.A.

      8-K - DBV Technologies S.A. (0001613780) (Filer)

      6/25/25 4:32:27 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by DBV Technologies S.A.

      S-8 - DBV Technologies S.A. (0001613780) (Filer)

      6/24/25 4:06:11 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by DBV Technologies S.A.

      8-K - DBV Technologies S.A. (0001613780) (Filer)

      6/11/25 4:05:24 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DBVT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old

      Châtillon, France, June 25, 2025 DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old First subject screened at the Respiratory Medicine Research Institute of Michigan with Dr. Jeffrey Leflein acting as Principal InvestigatorAdditional sites, including Allergy and Asthma Center of Minnesota and Hamilton Allergy and Immunology Clinic of Ontario, Canada have been activated and are scheduling screenings DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today provided an update on the progress on the Company's COMFORT Toddlers supplemental safety study using the Viaskin® Peanut patc

      6/25/25 4:15:00 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Technologies to Participate in Upcoming EAACI Congress 2025

      Châtillon, France, June 12, 2025 DBV Technologies to Participate in Upcoming EAACI Congress 2025 DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 13 – 16, 2025, in Glasgow, United Kingdom. DBV will present two posters and will also host a symposium and exhibit booth in the EAACI exhibit hall. Data to be presented during the scientific sessions will describe the reduced rate of reactions from accidental peanut consumption (APC) with the VIASKIN® peanut patch versus placebo in Year 2 of the Company's EPITOPE open-label extension (OLE) trial, as w

      6/12/25 4:05:00 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting

      Châtillon, France, June 11, 2025 DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company (the "Company"), held its Combined General Meeting (the "General Meeting"). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company's shareholders approved all resolutions submitted by the Board of Directors. The resolutions and the voting results are posted on the Investors/Annual General Meetings section of the Company's website: https://dbv-technologies.com/events/2025-annual-general-meeting/. About DBV TechnologiesDB

      6/11/25 4:30:00 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DBVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman resumed coverage on DBV Technologies with a new price target

      Goldman resumed coverage of DBV Technologies with a rating of Sell and set a new price target of $7.25

      5/29/25 8:17:33 AM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Technologies upgraded by Societe Generale

      Societe Generale upgraded DBV Technologies from Hold to Buy

      1/4/23 7:23:06 AM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Technologies downgraded by Goldman

      Goldman downgraded DBV Technologies from Neutral to Sell

      12/16/22 7:41:19 AM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DBVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Mohideen Pharis sold $730 worth of Ordinary Shares (397 units at $1.84), decreasing direct ownership by 0.36% to 110,113 units (SEC Form 4)

      4 - DBV Technologies S.A. (0001613780) (Issuer)

      5/27/25 4:10:06 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Epic Bpifrance claimed ownership of 10,898,595 units of Ordinary Shares (SEC Form 3)

      3 - DBV Technologies S.A. (0001613780) (Issuer)

      5/20/25 4:01:38 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Bpifrance Investissement S.A.S. claimed ownership of 226,133 units of Ordinary Shares (SEC Form 3)

      3 - DBV Technologies S.A. (0001613780) (Issuer)

      4/24/25 4:01:16 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DBVT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Tasse Daniel bought $14,188 worth of Ordinary Shares (17,094 units at $0.83) (SEC Form 4)

      4 - DBV Technologies S.A. (0001613780) (Issuer)

      3/11/24 4:15:38 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ndu Adora bought $1,624 worth of Ordinary Shares (1,825 units at $0.89) (SEC Form 4)

      4 - DBV Technologies S.A. (0001613780) (Issuer)

      2/8/24 5:02:03 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DBVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by DBV Technologies S.A.

      SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)

      11/14/24 4:55:56 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by DBV Technologies S.A. (Amendment)

      SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)

      2/14/24 8:56:45 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by DBV Technologies S.A. (Amendment)

      SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)

      2/14/24 4:06:12 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DBVT
    Leadership Updates

    Live Leadership Updates

    See more
    • DBV Technologies Reports First Quarter 2024 Financial Results and Business Update

      Montrouge, France, May 7, 2024 DBV Technologies Reports First Quarter 2024 Financial Results and Business Update VITESSE enrollment on track to screen last patient by Q3 2024Appointment of Robert Pietrusko, PharmD to Chief Regulatory OfficerQ1 2024 closes with a cash balance of $101.5 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the first quarter 2024. The quarterly financial statements were approved by the Board of Directors on May 7, 2024. Recent

      5/7/24 4:30:00 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer

      Montrouge, France, October 16, 2023 DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Virginie Boucinha as its Chief Financial Officer, effective November 6, 2023. An experienced financial and operations executive, Virginie will report directly to Daniel Tassé, Chief Executive Officer, and serve as a member of the Executive Committee. "I am pleased to welcome Virginie to the DBV Executive Committee to lead our global financial organization," said Daniel Tassé, Chief Executive Officer, DBV Tech

      10/16/23 2:00:00 AM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors

      Montrouge, France, October 3, 2022 DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors DBV Technologies (GREY:DBVTF), a clinical-stage biopharmaceutical company, today announced that Mr. Timothy E. Morris, Independent Director and Member of the Audit Committee of the Board of Directors ("the Board"), was appointed as Chairperson of the Board's Audit Committee in replacement of Ms. Viviane Monges, who resigned from the Board effective October 3, 2022. DBV also announced the Board's provisional appointment of Ms. Daniele Guyot-Caparros as Independent Director to fill Ms. Monges' vacancy, effective October

      10/3/22 4:30:00 PM ET
      $AQST
      $DBVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $DBVT
    Financials

    Live finance-specific insights

    See more
    • DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old

      Châtillon, France, June 25, 2025 DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old First subject screened at the Respiratory Medicine Research Institute of Michigan with Dr. Jeffrey Leflein acting as Principal InvestigatorAdditional sites, including Allergy and Asthma Center of Minnesota and Hamilton Allergy and Immunology Clinic of Ontario, Canada have been activated and are scheduling screenings DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today provided an update on the progress on the Company's COMFORT Toddlers supplemental safety study using the Viaskin® Peanut patc

      6/25/25 4:15:00 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

      Châtillon, France, January 8th, 2025 DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study EPITOPE OLE data demonstrates continued improvement in treatment benefit of VIASKIN® Peanut patch in toddlers 1 – 3 years through 36 months 68.2% of subjects completed the oral food challenge (~12-14 peanut kernels) without meeting stopping criteria, compared to 30.7% at month 12No treatment-related anaphylaxis or serious treatment-related Treatment-Emergent Adverse Events (TEAEs) occurred in year three of EPITOPE OLE    DBV also announced daily patch wear time data from EPITOPE that is supportive of the Company's proposed labeling approach shared with FD

      1/8/25 4:05:00 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

      Châtillon, France, December 11th, 2024 DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old DBV and FDA aligned on key study design elements for the COMFORT Toddlers study in 1 – 3 year-olds, including study size and wear time collection methodology and analysis COMFORT Toddlers study on-track to initiate in 2Q 2025Viaskin Peanut patch BLA submission for the Toddlers indication anticipated for 2H 2026 FDA confirmed criteria for post-marketing confirmatory study in toddlers 1 – 3 years-oldCompany to host investor webcast today at 5:00pm ET DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, tod

      12/11/24 4:05:00 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care